A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination With Cetuximab (Erbitux) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Trial Profile

A Phase 3 Open-Label, Randomized, Multicenter Study of Imprime PGG in Combination With Cetuximab (Erbitux) in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs PGG-glucan (Primary) ; Cetuximab
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PRIMUS
  • Sponsors Biothera
  • Most Recent Events

    • 30 Jan 2017 Status changed from active, no longer recruiting to discontinued due to enrollment challenges resulting from changing treatment patterns in the use of cetuximab, No patients remain on study.
    • 11 Oct 2016 Results (n=217) analysing relationship of anti-beta-glucan antibodies (ABA) and clinical outcomes, presented at the 41st European Society for Medical Oncology Congress.
    • 09 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top